RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Rallybio Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.35+0.07 (+0.43%)
Close on Oct 19, 2026
- Market cap
- $94.80M
- P/E (TTM)
- 2.1
- Dividend yield
- –
Share price
+$12.07 (+281.9%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Rallybio Corp saw revenue fall 15.1% to $646.00K over the twelve months to Jun 30, 2026.
Revenue
$646.00K
-15.1% vs. a year earlier
Operating income
-$27.72M
TTM Q2 2026
EPS, diluted
$7.92
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $94.80M
- P/E ratio
- 2.1
- Price to sales
- 146.74
- Price to book
- 1.00
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $646.00K
- Net income
- $45.55M
- EPS, diluted
- $7.92
- Book value per share
- $16.30
- Diluted shares
- 6M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$646.00K-15.1% YoY
Operating income
-$27.72M
Net income
$45.55M
EPS, diluted
$7.92
Free cash flow
–
Reported periodTrailing twelve months